Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells

Joyce M. van Dodewaard-de Jong, Saskia J A M Santegoets, Peter M. van de Ven, Jurjen Versluis, Henk M W Verheul, Tanja D. de Gruijl, Winald R. Gerritsen, Alfons J M van den Eertwegh

Research output: Contribution to journalArticle

Abstract

ABSTRACT: Previous vaccination studies in patients with castration-resistant prostate cancer (CRPC) showed improved survival without prolongation of progression-free survival (PFS). This might be explained by enhanced efficacy of subsequent therapies because of heightened immune status. We therefore evaluated the efficacy of chemotherapy in CRPC patients after immunotherapy. We retrospectively analyzed 28 patients who were treated with ipilimumab and GVAX, an allogeneic vaccine, and 21 patients who were randomized to GVAX or no vaccination. To study whether immune status was related to the efficacy of chemotherapy, frequencies of myeloid and lymphocyte subsets were determined. Of 28 patients treated with GVAX and ipilimumab, 23 patients received docetaxel and 13 patients mitoxantrone. Median PFS after docetaxel was 6.4 mo (range 0.8–11.2), while median PFS after mitoxantrone was markedly longer than expected (4.8 mo; range 1.4–13.7). High CD8+ICOS+ Tcell/Treg and pDC/mMDSC ratios were associated with relatively long PFS after mitoxantrone, suggesting a correlation between activated immune status and benefit of mitoxantrone. Analysis of 21 patients, randomized to GVAX or not, revealed a median PFS after docetaxel of 9.9 mo for vaccinated patients and 7.1 mo for unvaccinated patients. Interestingly, PFS after mitoxantrone (n = 14) was significantly longer in vaccinated patients as compared to controls (5.9 vs. 1.6 mo, p = 0.0048). In conclusion, mitoxantrone seems more effective in CRPC patients after immunotherapy, which may be related to the immune-stimulating effect of mitoxantrone in patients with heightened antitumor immunity. As this was a retrospective study with limited sample size, prospective studies are warranted to definitively show proof of principle.

Original languageEnglish (US)
JournalOncoImmunology
Volume5
Issue number4
DOIs
StatePublished - Apr 2 2016
Externally publishedYes

Fingerprint

Mitoxantrone
Castration
Granulocyte-Macrophage Colony-Stimulating Factor
Prostatic Neoplasms
Vaccination
docetaxel
Disease-Free Survival
Immunotherapy
Drug Therapy
Lymphocyte Subsets
Sample Size
Immunity

Keywords

  • Cancer vaccines
  • chemotherapy
  • docetaxel
  • GVAX
  • immunotherapy
  • mitoxantrone
  • prostate cancer

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

van Dodewaard-de Jong, J. M., Santegoets, S. J. A. M., van de Ven, P. M., Versluis, J., Verheul, H. M. W., de Gruijl, T. D., ... van den Eertwegh, A. J. M. (2016). Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. OncoImmunology, 5(4). https://doi.org/10.1080/2162402X.2015.1105431

Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. / van Dodewaard-de Jong, Joyce M.; Santegoets, Saskia J A M; van de Ven, Peter M.; Versluis, Jurjen; Verheul, Henk M W; de Gruijl, Tanja D.; Gerritsen, Winald R.; van den Eertwegh, Alfons J M.

In: OncoImmunology, Vol. 5, No. 4, 02.04.2016.

Research output: Contribution to journalArticle

van Dodewaard-de Jong, JM, Santegoets, SJAM, van de Ven, PM, Versluis, J, Verheul, HMW, de Gruijl, TD, Gerritsen, WR & van den Eertwegh, AJM 2016, 'Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells', OncoImmunology, vol. 5, no. 4. https://doi.org/10.1080/2162402X.2015.1105431
van Dodewaard-de Jong, Joyce M. ; Santegoets, Saskia J A M ; van de Ven, Peter M. ; Versluis, Jurjen ; Verheul, Henk M W ; de Gruijl, Tanja D. ; Gerritsen, Winald R. ; van den Eertwegh, Alfons J M. / Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. In: OncoImmunology. 2016 ; Vol. 5, No. 4.
@article{e720802c89bb4ceb80f7f51bf17677ef,
title = "Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells",
abstract = "ABSTRACT: Previous vaccination studies in patients with castration-resistant prostate cancer (CRPC) showed improved survival without prolongation of progression-free survival (PFS). This might be explained by enhanced efficacy of subsequent therapies because of heightened immune status. We therefore evaluated the efficacy of chemotherapy in CRPC patients after immunotherapy. We retrospectively analyzed 28 patients who were treated with ipilimumab and GVAX, an allogeneic vaccine, and 21 patients who were randomized to GVAX or no vaccination. To study whether immune status was related to the efficacy of chemotherapy, frequencies of myeloid and lymphocyte subsets were determined. Of 28 patients treated with GVAX and ipilimumab, 23 patients received docetaxel and 13 patients mitoxantrone. Median PFS after docetaxel was 6.4 mo (range 0.8–11.2), while median PFS after mitoxantrone was markedly longer than expected (4.8 mo; range 1.4–13.7). High CD8+ICOS+ Tcell/Treg and pDC/mMDSC ratios were associated with relatively long PFS after mitoxantrone, suggesting a correlation between activated immune status and benefit of mitoxantrone. Analysis of 21 patients, randomized to GVAX or not, revealed a median PFS after docetaxel of 9.9 mo for vaccinated patients and 7.1 mo for unvaccinated patients. Interestingly, PFS after mitoxantrone (n = 14) was significantly longer in vaccinated patients as compared to controls (5.9 vs. 1.6 mo, p = 0.0048). In conclusion, mitoxantrone seems more effective in CRPC patients after immunotherapy, which may be related to the immune-stimulating effect of mitoxantrone in patients with heightened antitumor immunity. As this was a retrospective study with limited sample size, prospective studies are warranted to definitively show proof of principle.",
keywords = "Cancer vaccines, chemotherapy, docetaxel, GVAX, immunotherapy, mitoxantrone, prostate cancer",
author = "{van Dodewaard-de Jong}, {Joyce M.} and Santegoets, {Saskia J A M} and {van de Ven}, {Peter M.} and Jurjen Versluis and Verheul, {Henk M W} and {de Gruijl}, {Tanja D.} and Gerritsen, {Winald R.} and {van den Eertwegh}, {Alfons J M}",
year = "2016",
month = "4",
day = "2",
doi = "10.1080/2162402X.2015.1105431",
language = "English (US)",
volume = "5",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "4",

}

TY - JOUR

T1 - Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells

AU - van Dodewaard-de Jong, Joyce M.

AU - Santegoets, Saskia J A M

AU - van de Ven, Peter M.

AU - Versluis, Jurjen

AU - Verheul, Henk M W

AU - de Gruijl, Tanja D.

AU - Gerritsen, Winald R.

AU - van den Eertwegh, Alfons J M

PY - 2016/4/2

Y1 - 2016/4/2

N2 - ABSTRACT: Previous vaccination studies in patients with castration-resistant prostate cancer (CRPC) showed improved survival without prolongation of progression-free survival (PFS). This might be explained by enhanced efficacy of subsequent therapies because of heightened immune status. We therefore evaluated the efficacy of chemotherapy in CRPC patients after immunotherapy. We retrospectively analyzed 28 patients who were treated with ipilimumab and GVAX, an allogeneic vaccine, and 21 patients who were randomized to GVAX or no vaccination. To study whether immune status was related to the efficacy of chemotherapy, frequencies of myeloid and lymphocyte subsets were determined. Of 28 patients treated with GVAX and ipilimumab, 23 patients received docetaxel and 13 patients mitoxantrone. Median PFS after docetaxel was 6.4 mo (range 0.8–11.2), while median PFS after mitoxantrone was markedly longer than expected (4.8 mo; range 1.4–13.7). High CD8+ICOS+ Tcell/Treg and pDC/mMDSC ratios were associated with relatively long PFS after mitoxantrone, suggesting a correlation between activated immune status and benefit of mitoxantrone. Analysis of 21 patients, randomized to GVAX or not, revealed a median PFS after docetaxel of 9.9 mo for vaccinated patients and 7.1 mo for unvaccinated patients. Interestingly, PFS after mitoxantrone (n = 14) was significantly longer in vaccinated patients as compared to controls (5.9 vs. 1.6 mo, p = 0.0048). In conclusion, mitoxantrone seems more effective in CRPC patients after immunotherapy, which may be related to the immune-stimulating effect of mitoxantrone in patients with heightened antitumor immunity. As this was a retrospective study with limited sample size, prospective studies are warranted to definitively show proof of principle.

AB - ABSTRACT: Previous vaccination studies in patients with castration-resistant prostate cancer (CRPC) showed improved survival without prolongation of progression-free survival (PFS). This might be explained by enhanced efficacy of subsequent therapies because of heightened immune status. We therefore evaluated the efficacy of chemotherapy in CRPC patients after immunotherapy. We retrospectively analyzed 28 patients who were treated with ipilimumab and GVAX, an allogeneic vaccine, and 21 patients who were randomized to GVAX or no vaccination. To study whether immune status was related to the efficacy of chemotherapy, frequencies of myeloid and lymphocyte subsets were determined. Of 28 patients treated with GVAX and ipilimumab, 23 patients received docetaxel and 13 patients mitoxantrone. Median PFS after docetaxel was 6.4 mo (range 0.8–11.2), while median PFS after mitoxantrone was markedly longer than expected (4.8 mo; range 1.4–13.7). High CD8+ICOS+ Tcell/Treg and pDC/mMDSC ratios were associated with relatively long PFS after mitoxantrone, suggesting a correlation between activated immune status and benefit of mitoxantrone. Analysis of 21 patients, randomized to GVAX or not, revealed a median PFS after docetaxel of 9.9 mo for vaccinated patients and 7.1 mo for unvaccinated patients. Interestingly, PFS after mitoxantrone (n = 14) was significantly longer in vaccinated patients as compared to controls (5.9 vs. 1.6 mo, p = 0.0048). In conclusion, mitoxantrone seems more effective in CRPC patients after immunotherapy, which may be related to the immune-stimulating effect of mitoxantrone in patients with heightened antitumor immunity. As this was a retrospective study with limited sample size, prospective studies are warranted to definitively show proof of principle.

KW - Cancer vaccines

KW - chemotherapy

KW - docetaxel

KW - GVAX

KW - immunotherapy

KW - mitoxantrone

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84962795027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962795027&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2015.1105431

DO - 10.1080/2162402X.2015.1105431

M3 - Article

VL - 5

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 4

ER -